Canada markets close in 27 minutes

  • S&P/TSX

    19,434.37
    -121.78 (-0.62%)
     

  • S&P 500

    4,279.20
    +5.67 (+0.13%)
     

  • DOW

    33,570.39
    -48.49 (-0.14%)
     

  • CAD/USD

    0.7406
    +0.0007 (+0.09%)
     

  • CRUDE OIL

    93.86
    +3.47 (+3.84%)
     

  • Bitcoin CAD

    35,465.91
    +95.63 (+0.27%)
     

  • CMC Crypto 200

    563.16
    +0.51 (+0.09%)
     

  • GOLD FUTURES

    1,895.10
    -24.70 (-1.29%)
     

  • RUSSELL 2000

    1,784.78
    +23.17 (+1.32%)
     

  • 10-Yr Bond

    4.6260
    +0.0680 (+1.49%)
     

  • NASDAQ

    13,113.96
    +50.35 (+0.39%)
     

  • VOLATILITY

    18.24
    -0.70 (-3.70%)
     

  • FTSE

    7,593.22
    -32.50 (-0.43%)
     

  • NIKKEI 225

    32,371.90
    +56.85 (+0.18%)
     

  • CAD/EUR

    0.7043
    +0.0049 (+0.70%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND LOSSES AFTER TUESDAY'S STEEP SELL-OFF

Worries about higher interest rates, U.S. government shutdown continue to weigh

Why Janux Therapeutics Shares Rose 33.1% This Week

Jim Halley, The Motley Fool
·2 min read
Why Janux Therapeutics Shares Rose 33.1% This Week

Shares of Janux Therapeutics (NASDAQ: JANX), which specializes in immunotherapies to treat cancer, rose 33.1% this week, according to data from S&P Global Intelligence. The clinical-stage biopharmaceutical company's shares have been rising since it announced on Oct. 12 that its first patient had been dosed in its Phase 1 clinical trial of JANX007 to treat metastatic castration-resistant prostate cancer. The news was a milestone for Janux as JANX007 is the company's first product candidate using its Tumor Activated T Cell Engager (TRACTr) platform to engage T cells to fight tumors.

Continue reading